comparemela.com

Latest Breaking News On - Division of gynecologic oncology - Page 1 : comparemela.com

Jill Kolesar named next College of Pharmacy dean

Jill M. Kolesar, university research professor in the University of Kentucky College of Pharmacy and the Dr. Michael Karpf Endowed Chair in Precision Medicine, has been named dean of the University of Iowa College of Pharmacy. She will begin on July 15.

University-of-texas
Texas
United-states
San-antonio
American
Clark-stanford
Nicole-brogden
Don-letendre
Kevin-kregel
Jillm-kolesar
University-of-iowa
University-of-kentucky-college-medicine

Exploiting the Vulnerabilities of High-Grade Serous Ovarian Cancer Through WEE1 Inhibition

Joyce F. Liu, MD, MPH, provides insights on WEE1 which has emerged as a potentially targetable pathway in high-grade serous ovarian cancer.

Massachusetts
United-states
Boston
Dana-farber-cancer-institute
Colombo
Western
Sri-lanka
American
Joycef-liu
End-results-program
Zentalis-pharmaceuticals

EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 eFFECTOR Therapeutics, Inc. , a leader in the development of selective translation regulator inhibitors for the treatment of cancer,.

United-states
Panagiotis-konstantinopoulos
Michael-fitzhugh
Christopherm-calabrese
Kevin-gardner
Doug-warner
Lifesci-communications
Nasdaq
Professor-of-medicine-at-harvard-medical-school
Dana-farber-cancer-institute
Exchange-commission
Pfizer

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United-states
Doug-warner
Michael-fitzhugh
Panagiotis-konstantinopoulos
Kevin-gardner
Christopherm-calabrese
Effector-therapeutics-inc
Lifesci-communications
Exchange-commission
Nasdaq
Division-of-gynecologic-oncology
Pfizer

Dr Liu on the Rationale for Targeting Wee1 in Ovarian Cancer

Dr Liu on the Rationale for Targeting Wee1 in Ovarian Cancer
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Joycef-liu
Harvard-medical-school
Dana-farber-cancer-institute
Division-of-gynecologic-oncology
Gynecologic-oncology
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.